|
Sub-category:
Lymphoma, Adult
Category:
leukemia/Lymphoma (Adult)
Meeting:
2002 ASCO Annual Meeting
Abstract No:
1064
Citation:
Proc Am Soc Clin Oncol 21: 2002 (abstr 1064)
Author(s):
Russell J Schilder, Tom Witzig, Leo Gordon, Christos E Emmanouilides, Nancy L Bartlett, Ian W Flinn, Richard Ugoretz, Eric Ding, Myron S Czuczman, Christine A White, Fox Chase Cancer Ctr, Philadelphia, PA; Mayo Clinic, Rochester, MN; Northwestern University, Robert H. Lurie Cancer Center, Chicago, IL; University of California Los Angeles, Los Angeles, CA; Washington University, St Louis, MO; Johns Hopkins Oncology Center, Baltimore, MD; IDEC Pharmaceuticals Corp, San Diego, CA; Roswell Park Cancer Inst, Buffalo, NY.
Abstract:
90 Y ibritumomab tiuxetan is a radiolabeled antiùCD20 murine monoclonal antibody conjugate with significant therapeutic activity in patients with advanced, heavily pretreated NHL. In a randomized trial, patients with lowùgrade, follicular and CD20+ transformed NHL achieved an overall response rate of 80% compared with 56% for the rituximab control (Witzig TE: ASH 2000). This report addresses the ability to administer subsequent therapy following 90Y ibritumomab tiuxetan. In five clinical trials 152 patients have had antiùlymphoma treatment following 90Y ibritumomab tiuxetan therapy. Response data was available for the first subsequent therapy in 99 patients, including 48 from the randomized trial. Patients had relapsed or refractory indolent, transformed, aggressive or mantle cell NHL with no prior myeloablative therapy, ANC >1,500/mm3, and marrow involvement <25% and received 90Y ibritumomab tiuxetan, either 0.3 mCi/kg (platelets 100,000 ù 149,000/mm3) or 0.4 mCi/kg (platelets >150,000/mm3). At disease progression patients were treated at the discretion of their physician with a variety of regimens including single alkylating agents, CHOP, ESHAP, DHAP and high dose therapy with stem cell rescue and others. Responses were achieved in all categories of subsequent therapy. [table] ORRs were comparable to those commonly achieved with salvage therapy in advanced nonùHodgkin¦s lymphoma (NHL). These results demonstrate that further therapy is both feasible and potentially effective after 90Y ibritumomab radioimmunotherapy for NHL.
Overall Response Rate to First Therapy
After 90Y ibritumomab tiuxetan | Subsequent Therapy | All Zevalin Studies | Randomized Study | | | N/Total (%) | Zevalin Arm ù N/Total (%) | Rituximab Arm ù N/Total (%) | | All | 61/99 (62) | 17/24 (71) | 15/30 (50) | | Chemotherapy | 26/49 (53) | 8/11 (73) | 6/10 (60) | | Bioimmunotherapy* | 14/24 (58) | 5/9 (56) | 5/16 (31) | | Radiation | 20/25 (80) | 3/3 (100) | 4/4 (100) | | ABMT | 1/1 (100) | 1/1 (100) | - | *rituximab, interferon
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by Russell J Schilder:
Presentations by Russell J Schilder:
Educational Book Manuscripts by Russell J Schilder:
|
